AMG 510
Phase 1Active 1 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation
Conditions
Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation
Trial Timeline
Apr 28, 2020 → Jun 16, 2026
NCT ID
NCT04380753About AMG 510
AMG 510 is a phase 1 stage product being developed by Amgen for Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation. The current trial status is active. This product is registered under clinical trial identifier NCT04380753. Target conditions include Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation.
What happened to similar drugs?
0 of 2 similar drugs in Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
6
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04667234 | Pre-clinical | Completed |
| NCT04380753 | Phase 1 | Active |
| NCT05578859 | Phase 1 | Completed |
| NCT05571163 | Phase 1 | Completed |
| NCT05581758 | Phase 1 | Completed |
Competing Products
20 competing products in Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation